AbbVie’s dividend appeal is soaring, with a juicy 2.7% yield beating the S&P 500 and pharma averages—thanks to strong cash flow that supports a healthier payout ratio than its earnings suggest. Built on powerhouse immunology and oncology, the company’s rebounded from Humira’s patent loss with blockbuster drugs like Skyrizi and Rinvoq. Strategic acquisitions, including the $11B Apogee deal, are expanding its pipeline in inflammatory diseases, while Botox remains a cash-generating juggernaut—even beyond aesthetics, with migraine treatments and more approvals on the horizon.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
